Why is the Mesoblast (ASX:MSB) share price blasting 10% higher today?

It’s a good day to be a shareholder in the regenerative medicine company.

| More on:
Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.

Image source: Getty Images

The Mesoblast Limited (ASX: MSB) share price is shooting higher today despite the company’s silence.

In fact, the market hasn’t heard any price-sensitive news from the biotechnology company in two weeks.

Still, the company’s stock is well and truly in the green today. At the time of writing, the Mesoblast share price is $1.75, 9.69% higher than its previous close.

For context, the S&P/ASX 200 Index (ASX: XJO) is currently up 1.17%. Meanwhile, the All Ordinaries Index (ASX: XAO) has gained 1.29%.

Let’s take a look at the latest news from the company.

What’s going on with the Mesoblast share price?

At its current share price, Mesoblast has now officially recovered from its late-November dip.

The company released its results for the first quarter of financial year 2022 on 24 November.

Within them, it reported a US$2.3 million year-on-year revenue increase, bringing its takings for the quarter up to US$3.6 million.

The company also reduced its cash usage, its research and development expenses, and its manufacturing expenses.

Perhaps unsurprisingly, the market bid the Mesoblast share price higher on the back of its results, sending it to gain 1.7%. However, it tumbled 11.3% over the following 6 sessions.

Between then and now, the company has conducted its annual general meeting and announced findings regarding its Rexlemestrocel-L drug.

On Monday, the company announced the DREAM-HF Phase 3 trial of Rexlemestrocel-L in patients with chronic heart failure and low ejection fraction (HFrEF) found the greatest benefit from Rexlemestrocel-L is in HFrEF patients with diabetes, ischemia, or both.

While the news wasn’t marked as price-sensitive, the Mesoblast share price gained 3.5% on Monday.

Finally, potentially helping Mesoblast along today is the broader healthcare sector’s performance. The S&P/ASX 200 Health Care Index (ASX: XHJ) is currently up 0.6%, with nearly all its members recording gains.

While it’s not as stellar as the broader market’s performance, it’s still good news for the company and its peers.

Yet. despite today’s gains, the Mesoblast share price is still 22% lower than it was at the start of 2021. It’s not all bad though — it’s gained 5% since this time last month.

Should you invest $1,000 in Mesoblast right now?

Before you consider Mesoblast, you'll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Mesoblast wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of January 13th 2022

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares